Skip to Main content Skip to Navigation
Preprints, Working Papers, ...

A competitive activity-based protein profiling platform yields cell wall synthesis inhibitors active against replicating and non-replicating Mycobacterium tuberculosis

Abstract : ABSTRACT The identification and validation of a small molecule’s targets is a major bottleneck in the discovery process for tuberculosis antibiotics. Activity-based protein profiling (ABPP) is an efficient tool for determining a small molecule’s targets within complex proteomes. However, how target inhibition relates to biological activity is often left unexplored. Here we studied the effects of 1,2,3-triazole ureas on Mycobacterium tuberculosis ( Mtb ). After screening ~200 compounds, we focused on two inhibitors active against both exponentially replicating and hypoxia-induced drug-tolerant Mtb that form part of a four-compound structure-activity series. The compound with negligible activity revealed potential false positive targets not addressed in other ABPP studies. Biochemistry, computational docking, and morphological analysis confirmed that active compounds preferentially inhibit serine hydrolases with cell wall and lipid metabolism functions and that disruption of the cell wall underlies biological activity. Our findings showed that ABPP identifies the targets most likely relevant to a compound’s antibacterial activity.
Document type :
Preprints, Working Papers, ...
Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-03224900
Contributor : Jean-François Cavalier Connect in order to contact the contributor
Submitted on : Wednesday, May 12, 2021 - 9:04:40 AM
Last modification on : Wednesday, October 27, 2021 - 10:00:05 AM

Links full text

Identifiers

Collections

Citation

Michael Li, Hiren Patel, Armand Cognetta, Trever Smith, Ivy Mallick, et al.. A competitive activity-based protein profiling platform yields cell wall synthesis inhibitors active against replicating and non-replicating Mycobacterium tuberculosis. 2021. ⟨hal-03224900⟩

Share

Metrics

Record views

34